An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.Daniel Yick Chin Heng, Lori Wood, Toni K. Choueiri et al.|Journal of Clinical Oncology|2012Cited by 18
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).Daniel Yick Chin Heng, Toni K. Choueiri, Lori Wood et al.|Journal of Clinical Oncology|2012Cited by 8
A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.Daniel Yick Chin Heng, Lori Wood, Toni K. Choueiri et al.|Journal of Clinical Oncology|2012Cited by 6
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.Georg A. Bjarnason, J. A. Miller, Naveen S. Basappa et al.|Journal of Clinical Oncology|2013Cited by 5
Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).Rana R. McKay, Toni K. Choueiri, Nils Kroeger et al.|Journal of Clinical Oncology|2013Cited by 2